Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors

Annals of Oncology

Volumn 21, Issue 2, 2009, Pages 382-388

  Lim, W T ^a   Tan, E H ^a   Toh, C K ^a   Hee, S W ^a   Leong, S S ^a   Ang, P C S ^a   Wong, N S ^a   Chowbay, B ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Asian; Genexol PM; Pharmacokinetics; Phase 1; Weekly regime

Indexed keywords

DOCETAXEL; GENEXOL PM; LIPOSOME; MACROGOL; PACLITAXEL; POLYLACTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; COUGHING; CRANIAL NEUROPATHY; DERMATITIS; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEAD AND NECK CANCER; HUMAN; INSOMNIA; LUNG CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NASOPHARYNX CANCER; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 77949526367     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp315     Document Type: Article

References (28)

1. Crown J, O'Leary M. The taxanes: an update. Lancet 2000; 355: 1176-1178.
2. Rowinsky EK. The taxanes: dosing and scheduling considerations. Oncology 1997; 11: 07-19.
3. Jordan MA, Toso RJ, Thrower D et al. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci U S A 1993; 90: 9552-9556.
4. Torres K, Horwitz SB. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 1998; 58: 3620-3626.
5. Sonnichsen DS, Hurwitz CA, Pratt CB et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumours. J Clin Oncol 1994; 12: 532-538.
6. Gianni L, Kearns CM, Gianni A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180-190.
7. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37: 1590-1598.
8. Webster L, Linsenmeyer M, Millward M et al. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 1993; 85: 1685-1690.
9. Rischin D, Webster LK, Millward MJ et al. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 1996; 88: 1297-1301.
10. Sparreboom A, Verweij J, van der Burg ME et al. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 1998; 4: 1937-1942.
11. Bardelmeijer HA, Ouwehand M, Malingre MM et al. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. Cancer Chemother Pharmacol 2002; 49: 119-125.
12. Malingre MM, Schellens JH, Van Tellingen O et al. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br J Cancer 2001; 85: 1472-1477.
13. Gelderblom H, Mross K, ten Tije AJ et al. Comparative pharmacokinetics of unbound paclitaxel during 1-and 3-hour infusions. J Clin Oncol 2002; 20: 574-581.
14. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998; 90: 300-306.
15. Szebeni J, Alving CR, Savay S et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 2001; 1: 721-735.
16. Weiss RB, Donehower RC, Wiernik PH et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-1268.
17. Khan A, McNally D, Tutschka PJ, Bilgrami S. Paclitaxel-induced acute bilateral pneumonitis. Ann Pharmacother 1997; 31: 1471-1474.
18. Windebank AJ, Blexrud MD, de Groen PC. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 1994; 268: 1051-1056.
19. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994; 5: 495-505.
20. Lesser GJ, Grossman SA, Eller S, Rowinsky EK. The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study. Cancer Chemother Pharmacol 1995; 37: 173-178.
21. Kim SC, Kim DW, Shim YH et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001; 72: 191-202.
22. Kim TY, Kim DW, Chung JY et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004; 10: 3708-3716.
23. Lee KS, Chung HC, Im SA et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008; 108: 241-250.
24. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
25. Willey TA, Bekos EJ, Gaver RC et al. High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol®) in human plasma. J Chromatogr 1993; 621: 231-238.
26. Kim DW, Kim SY, Kim HK et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007; 18: 2009-2014.
27. Saif MW, Rubin MS, Figueroa JA, Kerr RO. Multicenter phase II trial of Genexol-PM (GPM), a novel Cremophor-free, polymeric micelle formulation of paclitaxel in patients with advanced pancreatic cancer (APC): final results. In ASCO 2008 Gastrointestinal Cancers Symposium, Orlando, FL, USA (Abstr 269).
28. Azria D, Magné N, Zouhair A et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005; 31: 555-570.